Literature DB >> 15459315

Remission of a refractory, anaplastic large-cell lymphoma after treatment with daclizumab.

Ola Lindén.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15459315     DOI： 10.1056/NEJM200409303511424

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  4 in total

Review 1.  Brentuximab vedotin.

Authors:  Niels W C J van de Donk; Eugen Dhimolea
Journal:  MAbs       Date:  2012-07-01       Impact factor: 5.857

2.  Ongoing development of monoclonal antibodies and antibody drug-conjugates in lymphoma.

Authors:  Eileen M Boyle; Franck Morschhauser
Journal:  Curr Oncol Rep       Date:  2011-10       Impact factor: 5.075

3.  Increased frequency of regulatory T cells in peripheral blood and tumour infiltrating lymphocytes in colorectal cancer patients.

Authors:  Khoon Lin Ling; Sarah E Pratap; Gaynor J Bates; Baljit Singh; Neil J Mortensen; Bruce D George; Bryan F Warren; Juan Piris; Giovanna Roncador; Stephen B Fox; Alison H Banham; Vincenzo Cerundolo
Journal:  Cancer Immun       Date:  2007-03-28

Review 4.  Monoclonal Antibody Therapies for Hematological Malignancies: Not Just Lineage-Specific Targets.

Authors:  Carlos Cuesta-Mateos; Ana Alcaraz-Serna; Beatriz Somovilla-Crespo; Cecilia Muñoz-Calleja
Journal:  Front Immunol       Date:  2018-01-17       Impact factor: 7.561
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.